

研究成果の刊行に関する一覧表

書籍 (該当なし)

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hara A, Wada T, Sada KE, Amano K, Doibashi H, Harigai M, Takasaki Y, Yamada H, Hasegawa H, Hayashi T, Fujimoto S, Muso E, Kawakami T, Homma S, Yoshida M, Hirahashi J, Ogawa N, Ito S, Makino H, Arimura Y	Research Committee on Intractable Vasculitides and the Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline . Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan	A Nationwide, Prospective Cohort Study. J Rheumatol	45(4)	521-528	2018

<p>Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takakeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Yoshio T, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama J, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.</p>	<p>Regional variations in the Japan nephrotic syndrome cohort study. Clin Exp Nephrol</p>	<p>22(6)</p>	<p>1266-1280</p>	<p>2018</p>
<p>Harigai M, Nagasaka K, Amano K, Bandono M, Dobashi H, Kawakami T, Kishibe K, Murakawa Y, Usui J, Wada T, Tanaka E, Nango E, Nakayama T, Tsutsumino M, Yamagata K, Hosonuma S, Arimura Y</p>	<p>2017 Clinical practice guidelines of the Japanese Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis</p>	<p>Mod Rheumatol</p>	<p>29(1)</p>	<p>20-30</p>
<p>Kanda E, Kashihara N, Matsushita K, Usui T, Okada H, Iseki K, Mikami K, Tanaka T, Wada T, Watada H, Ueki K, Nangaku M</p>	<p>Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease. Guidelines for clinical evaluation of chronic kidney disease</p>	<p>AMED research on regulatory science of pharmaceuticals and medical devices. Clin Exp Nephrol</p>	<p>22(6)</p>	<p>1446-1475</p>

Kato Y, Azuma K, Sameda H, Shiokawa M, Chiba T	Case of IgG4-associated sclerosing cholangitis with normal serum IgG4 concentration, diagnosed by antilaminin 511-E8 antibody: a novel autoantibody in patients with autoimmune pancreatitis.	Gut	in press		2019
Wallace ZS, Zhang Y, Perugino CA, Nafden R, Choi HK, Steiner JH; ACR/EULAR IgG4-RD Classification Criteria Committee.	Clinical phenotypes of IgG4-related disease: An analysis of two international cross-sectional cohorts.	Ann Rheum Dis	78(3)	406-412	2019
Kamisawa T, Nakazawa T, Tazuma S, Zenon Y, Tanaka A, Ohara H, Muraki T, Inoue K, Inoue D, Nishino T, Naitoh I, Itoi T, Notohara K, Kanno A, Kubota K, Hirano K, Isayama H, Shimizu K, Tsuyuguchi T, Shimosegawa T, Kawa S, Chiba T, Okazaki K, Takikawa H, Kimura W, Unno T, Yoshida M	Clinical practice guidelines for IgG4-related sclerosing cholangitis.	J Hepato-Biliary Pancreat Sci	DOI: 10.1002/jhbp.596		2019
Shiokawa M, Kodama Y, Sekiguchi K, Kikawada M, Tomono T, Kuriyama K, Yamazaki H, Morita T, Marui S, Sogabe Y, Kakiuchi N, Matsumori T, Mima A, Nishikawa Y, Ueda T, Tsuda M, Yamauchi Y, Sakuma Y, Maruno T, Uza N, Tsuruyama T, Mimori T, Seno H, Chiba T	Autoimmune pancreatitis (AIP), a major manifestation of immunoglobulin G4-related disease (IgG4-RD).	Sci Transl Med	8 (10)	453	2018

Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, Uchida K, Okazaki K, Ito T, Kawa S, Yamada K, Kawano M, Hirata S, Tanaka Y, Moriyama M, Nakamura S, Kamisawa T, Matsui S, Tsuboi H, Sumida T, Shibata M, Goto H, Sato Y, Yoshino T, Mimori T	Factors in glucocorticoid regimens associated with treatment response and relapses in IgG4-related disease: a multicenter study	Sci Rep	8 (1)	10262	2018
Ito T, Kawa S, Matsumoto A, Kubota K, Kamisawa T, Okazaki K, Hirano K, Hirooka Y, Uchida K, Masuda A, Ohara H, Shimizu K, Arakura N, Masamune A, Kanno A, Sakagami J, Itoi T, Ito T, Ueki T, Nishino T, Inui K, Mizuno N, Yoshida H, Sugiyama M, Iwasaki E, Irisawa A, Shimosegawa T, Chiba T.	Risk factors for pancreatic stone formation in type 1 autoimmune pancreatitis: A long-term Japanese multicenter analysis of 624 patients.	Pancreas	48	49-54	2018
Kasai S, Sakai R, Koike R, Kohsaka H, Miyasaka N, Harigai M.	Higher risk of hospitalized infection, cardiovascular disease, and fracture in patients with rheumatoid arthritis determined using the Japanese health insurance database.	Mod Rheumatol.	28	1-7	2018 Nov
Yamanaka H, Hirose T, Endo Y, Sugiyama N, Fukuma Y, Morishima Y, Sugiyama N, Yoshii N, Miyasaka N, Koike T.	Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance.	Mod Rheumatol.	20	1-10	2018 Sep

Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T; SURPRISE study group.	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomized controlled study (the second year of the SURPRISE study).	Ann Rheum Dis	77(9)	1268-1275	2018 Sep
Takeuchi T, Harigami M, Tanaka Y, Yamanaoka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Ukyo Y, Ishii Y, Yoshinari T, Baker D; GO-MONO study group.	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.	Mod Rheumatol.	8(5)	770-779	2018 Sep
Sakai R, Kasai S, Hirano F, Harada S, Kihara M, Yokoyama W, Tsutsumino M, Nagasaka K, Koike R, Yamanaka H, Miyasaka N, Harigami M.	No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.	Int J Rheum Dis.	21(9)	1670-1677	2018 Sep
Umezawa N, Kawahata K, Mizoguchi F, Kimura N, Yoshihashi-Nakazato Y, Miyasaka N, Kohsaka H.	Interleukin-23 as a therapeutic target for inflammatory myopathies.	Sci Rep.	8(1)	5498	2018 Apr 3
Oba K, Horie N, Saito N, Saito K, Takeuchi T, Mimori T, Miyasaka N, Koike T, Tanaka Y.	Remission induction by raising the dose of Remicade in RA (RRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis.	Contemp Clin Trials Commun.	8	49-54	2017 Aug 17

井田博幸	小児慢性特定疾患児童 成人移行期支援モデル 事業	医学のあゆ み	265	901-906	2018年6月9 日
井田博幸	Gaucher病に対する基質 合成抑制療法	小児内科	50	1577-1580	2018年10月 1日
Hiroo Hoshina, Yohta a Shimada, Takashi Higuchi, Hiroshi K obayashi, Hiroyuki Ida, Toya Ohashi.	Chaperone effect of s ulfated disaccharide from heparin on mutan t iduronate-2-sulfata se in mucopolysacchar idosis type II	Molecular G enetics and Metabolism	123	118-122	2018
井田博幸	ライソゾーム病の基礎 と臨床	医学のあゆ み	別冊	31-36	2019年1月1 5日
Yoshihiko Furusaw a, Izumi Yamaguch i, Naoko Yagishit a, Kazumasa Tanzaw a, Fumihiko Matsud a, Yoshihisa Yaman o, RADDAR - J Resea rch and Developmen t Group	National platform for Rare Diseases Data R egistry of Japan	Learn Healt h Sys	DOI: 10. 1002/lrh 2.10080.		2019